InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Monday, 10/21/2019 12:45:26 PM

Monday, October 21, 2019 12:45:26 PM

Post# of 284
News: $SGEN Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer

-HER2CLIMB Trial Met Primary Endpoint and Both Key Secondary Endpoints- -Global Regulatory Strategy Includes NDA Submission to U.S. FDA Planned for First Quarter of 2020- -Data to be Presented at the 2019 San Antonio Breast Cancer Symposium- -Company to Host Conference Call ...

Find out more SGEN - Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SGEN News